Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 30, 2017

DAIC’s Website Broke 1 Million Pageviews; Two Key TCT Takeaways

DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and speak to readers at site visits and conferences, one of the clearest views we have of reader interests is based on what they are reading on our website, e-newsletters and digital editions. We have responded to these analytics in what we publish and how we cover new cardiovascular technology. The result has been a big increase in our online readership over the past year. For the first time, DAIC’s website broke 1 million pageviews in November 2016. We wanted to thank our readers for helping us reach this milestone. 

See a list of the “Most Popular Cardiology Articles of 2016 From DAIC.”

See the list of “Top Cardiology Videos on DAIC in 2016.”

 

Two Key Takeaways at TCT 2016

After decompressing from the interventional information overload at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in November, I felt there were two big technology takeaways requiring an in-depth review.  These included the EXCEL Trial and the results of three studies that compared bioresorbable polymer metallic drug-eluting stents (DES) to the current standard durable polymer metallic DES. 

The EXCEL Trial was the biggest news at TCT.16. It compared the use of the Abbott Xience V DES to coronary artery bypass graft (CABG) surgery in patients with left main disease. The result of this large randomized trial was that both have equal outcomes. You can read the article with more detail at  "Stents Have Equal Outcomes to Bypass Surgery in EXCEL Trial."

Durable drug-carrier polymers on DES have been implicated as the cause of late-stent thrombosis, which has led to long-duration use of dual antiplatelet therapy (DAPT). The introduction of bioresorbable polymers was expected to eliminate late events and the need for long-term DAPT. However, results from three trials of bioresorbable polymer DES showed equal outcomes and no apparent benefit. Read more detail and here Boston Scientific's response to the data in the article "Bioresorbable Polymers on Metallic Stents Show No Superiority to Durable Polymer Stents."

 

New DAIC Editorial Board Members

DAIC recently added two new Editorial Board members who are experts in cutting-edge interventional and structural heart technologies. The first is Azeem Latib, M.D., an interventional cardiologist at Università Vita-Salute San Raffaele Milano, Milan, Italy. He is a regular speaker at  TCT and other conferences. His research interests include new transcatheter heart valve repair and replacement technologies and bioresorbable stents. Read his recent article on the Cardioband annuloplasty device, "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."

Our second new board member is Torsten Vahl, M.D., director of experimental and translational research and assistant professor of medicine at Columbia University Medical Center, The Center for Interventional Vascular Therapy. He also is a regular speaker at TCT and is involved in bleeding-edge research and trials for new structural heart interventions. Watch a video interview with Vahl at TCT 2016, "Transcatheter Valve Technology Advancements at TCT 2016."
 

Related Content

4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Overlay Init